Key result
PCI linked to lower 3-year MACCE across reduced eGFR strata in NSTEMI, but not normal kidney function.
Why the study?
Does percutaneous coronary intervention compared with non-PCI medical management reduce 3-year major adverse cardiac and cerebrovascular events across different baseline renal function strata in patients with NSTEMI?
Cohort (n=15,255)
Yes
Does percutaneous coronary intervention compared with non-PCI medical management reduce 3-year major adverse cardiac and cerebrovascular events across different baseline renal function strata in patients with NSTEMI?
Answers are grounded in this paper and cite their sources.
In patients with NSTEMI, PCI is associated with significantly lower 3-year risks of MACCE and mortality compared with medical management across all stages of impaired renal function (eGFR <90 mL/min/1.73 m2), supporting invasive management rather than deferring revascularization solely due to chronic kidney disease.
BACKGROUND Renal dysfunction increases adverse outcomes in non-ST-segment elevation myocardial infarction (NSTEMI), but evidence comparing percutaneous coronary intervention (PCI) with non-PCI by renal function is limited. OBJECTIVES The authors aimed to compare 3-year outcomes of PCI versus non-PCI by baseline renal function in NSTEMI. METHODS We stratified 15,255 NSTEMI patients by estimated glomerular filtration rate (eGFR; ≥90, 60-89, 30-59, and <30 mL/min/1.73 m2). Primary outcome was 3-year major adverse cardiac and cerebrovascular events (MACCE; defined as all-cause death, recurrent myocardial infarction, or stroke). Multivariable-adjusted Cox regression was performed. Median follow-up was 36.0 months (IQR: 36.0-36.0 months; 40,097 person-years). RESULTS Worsening renal function was associated with higher MACCE and mortality (all P < 0.001), except between eGFR ≥90 and 60-89. Compared with non-PCI, PCI was associated with lower adjusted risks in the eGFR 60-89, 30-59, and <30 strata, respectively, regarding MACCE (HR [95% CI]: 0.58 [0.47-0.71]; 0.66 [0.53-0.82]; 0.60 [0.48-0.75]), all-cause mortality (HR [95% CI]: 0.47 [0.37-0.60]; 0.57 [0.45-0.72]; 0.59 [0.47-0.76]), and cardiovascular mortality (HR [95% CI]: 0.48 [0.34-0.66]; 0.53 [0.39-0.70]; 0.56 [0.41-0.75]) (all P < 0.001), but not in eGFR ≥90 MACCE (HR: 0.83 [95% CI: 0.64-1.07]; P = 0.158). Significant interaction was observed only for all-cause mortality (P = 0.044). CONCLUSIONS In NSTEMI, worsening renal function was associated with higher long-term adverse outcomes. PCI was associated with lower risks across most renal function strata, but not in eGFR ≥90.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2026) conducted a cohort in Non-ST-segment elevation myocardial infarction (NSTEMI) stratified by baseline renal function (n=15,255). Percutaneous coronary intervention (PCI) vs. Non-PCI (medical therapy alone / nonrevascularization) was evaluated on 3-year major adverse cardiac and cerebrovascular events (MACCE: composite of all-cause death, recurrent myocardial infarction, or stroke) (HR 0.83 (eGFR >=90), HR 0.58 (eGFR 60-89), HR 0.66 (eGFR 30-59), HR 0.60 (eGFR <30), 95% CI 0.64-1.07 (eGFR >=90), 0.47-0.71 (eGFR 60-89), 0.53-0.82 (eGFR 30-59), 0.48-0.75 (eGFR <30), p=<0.001 (for eGFR 60-89, 30-59, and <30 strata; P=0.158 for eGFR >=90)). Percutaneous coronary intervention was associated with lower 3-year MACCE risks in NSTEMI patients with eGFR 60-89, 30-59, and <30, but not eGFR >=90.
Synapse has enriched 10 related papers. Consider them for comparative context: